Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma

Competing interests

D.A. has acted as a consultant and/or advisor of Astellas, BMS, Century Therapuetics and has received research funding from Astellas, Merck and Seagen. J.R. has acted as a consultant and/or advisor of Aadi Biosciences, Aktis, Alligator Biosciences, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BMS, Boehringer Ingelheim, Century Therapeutics, EMD-Serono, Gilead, Hengrui, Imvax, Janssen, Loxo, Merck, Pfizer, Seagen and Tyra Biosciences and has received research funding from Acrivon, Astellas, AstraZeneca, Bayer, Loxo and Seagen.

留言 (0)

沒有登入
gif